(Q45120611)

English

Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure

scientific article published in November 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Wilson S Colucci

object named as

Wilson S Colucci

7

0 references

Douglas L. Mann

object named as

Douglas Mann

5

0 references

author name string

Ronald S Freudenberger

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Richard P Schwarz

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Joanne Brown

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Alan Moore

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Michael M Givertz

6

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Joshua M Hare

8

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

language of work or name

0 references

publication date

1 November 2004

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1509-1516

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

The purine path to chemotherapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Allopurinol improves endothelial dysfunction in chronic heart failure

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Depression of peak force without altering calcium sensitivity by the superoxide anion in chemically skinned cardiac muscle of rat

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Cardiac resynchronization in chronic heart failure

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.11.1509

21 January 2018

Identifiers

10.1517/13543784.13.11.1509

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45120611&oldid=2066433697"